Not finding it? Sign in to also search OpenAlex live.
-
Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L12020 Cancer Immunology Immunotherapy article Immunology and Microbiology Immune Cell Function and Interaction Open access cited by 1 patent
Anna M. Makowska, Selina Meier, Lian Shen, Pierre Busson, Valentin M. D. Baloche, Udo Kontny
46citations -
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01.2023 Journal of Clinical Oncology conference-abstract Medicine Cancer Immunotherapy and Biomarkers Open access
Kristoffer Staal Rohrberg, Mariana Brandão, Eduardo Castañón Álvarez, Enriqueta Felip, Eelke Hiddo Gort, T. Jeroen N. Hiltermann, +14 more
22citations -
Gammaherpesvirus infection impairs lung fibrosis resolution through PD-L1+ fibroblasts and PD-1+ CD8+ T cell interaction2026 Mucosal Immunology article Medicine Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Open access
Laura Kempen, Domien Vanneste, Justine Javaux, Lorène Dams, R Sandor, M. Pathammavong, +14 more
0citations -
A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer
Hanieh Abedian Kalkhoran, J. Zwaveling, Bert N. Storm, Sylvia A. van Laar, Johanneke E.A. Portielje, Henk Codrington, +4 more
14citations -
1176P Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC)2022 Annals of Oncology article Immunology and Microbiology Immunotherapy and Immune Responses Open access
J.F. Vansteenkiste, I. Demedts, E. Pons-Tostivint, B. Biesma, F. Borm, B. Colinet, +14 more
5citations -
Stem-like PD-1 + TCF-1 + CD8 + T cells result from helpless priming and rely on CD4 + T-cell help to complete their cytotoxic effector differentiation2026 Journal for ImmunoTherapy of Cancer article Immunology and Microbiology T-cell and B-cell Immunology Open access
Julia Busselaar, Douwe M. T. Bosma, Mo D. Staal, Xin Lei, Yanling Xiao, Jannie G. Borst
2citations -
Progenitor exhausted PD-1+ T cells are cellular targets of immune checkpoint inhibition in atherosclerosis2025 Nature Cardiovascular Research article Immunology and Microbiology Atherosclerosis and Cardiovascular Diseases Open access
Megan Mulholland, Anthi Chalou, Marie A.C. Depuydt, Yinda Yu, Shiying Lin, Klara Tallbäck, +10 more
15citations -
Stimulation of the PD-1 Pathway Decreases Atherosclerotic Lesion Development in Ldlr Deficient Mice2021 Frontiers in Cardiovascular Medicine article Immunology and Microbiology Atherosclerosis and Cardiovascular Diseases Open access cited by 1 patent
Hendrika W. Grievink, Virginia Smit, Robin A.F. Verwilligen, Mireia N. A. Bernabé Kleijn, Diede Smeets, Christoph J. Binder, +5 more
35citations -
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors2020 Journal for ImmunoTherapy of Cancer article Medicine Cancer Immunotherapy and Biomarkers Open access cited by 1 patent
Aung Naing, Justin F. Gainor, Hans A. J. Gelderblom, Patrick M. Forde, Marcus Otho Butler, Chia‐Chi Lin, +11 more
86citations -
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors2021 Clinical Cancer Research article Medicine Cancer Immunotherapy and Biomarkers Open access cited by 7 patents
Giuseppe Curigliano, Hans A. J. Gelderblom, Nicolas Mach, Toshihiko Doi, David Wai-Meng Tai, Patrick M. Forde, +13 more
359citations -
Data from Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
Giuseppe Curigliano, Hans A. J. Gelderblom, Nicolas Mach, Toshihiko Doi, David Wai-Meng Tai, Patrick M. Forde, +13 more
0citations -
Data from Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
Giuseppe Curigliano, Hans A. J. Gelderblom, Nicolas Mach, Toshihiko Doi, David Wai-Meng Tai, Patrick M. Forde, +13 more
0citations -
A PD-1-ST2 axis controls Th2 effector function in tissue via a metabolic checkpoint2023 bioRxiv (Cold Spring Harbor Laboratory) preprint Immunology and Microbiology IL-33, ST2, and ILC Pathways Open access
Graham A. Heieis, Bart Everts, Craig W. Roberts, Rick M. Maizels, Georgia Perona‐Wright
1citations -
Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy2021 Journal for ImmunoTherapy of Cancer article Medicine Cancer Immunotherapy and Biomarkers Open access cited by 3 patents
Kim E. Kortekaas, Saskia J A M Santegoets, Liselotte Tas, Ilina Ehsan, Pornpimol Charoentong, Helena C. van Doorn, +3 more
28citations -
Intensity- and time-matched acute interval and continuous endurance exercise similarly induce an anti-inflammatory environment in recreationally active runners: focus on PD-1 expression in Tregs and the IL-6/IL-10 axis2023 European Journal of Applied Physiology article Medicine Exercise and Physiological Responses Open access
Sebastian Proschinger, Alexander Schenk, Inga Weßels, Lars Donath, Ludwig Rappelt, Alan J. Metcalfe, +1 more
13citations -
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes2020 Cancer Cell article Medicine Cancer Immunotherapy and Biomarkers Open access cited by 3 patents
Floris F. Dammeijer, Mandy van Gulijk, Evalyn E.A.P. Mulder, Melanie M. Lukkes, Larissa Klaase, Thierry P. P. van den Bosch, +18 more
720citations